Aviva PLC Cuts Holdings in Pfizer Inc. (PFE)
Aviva PLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 0.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,616,234 shares of the biopharmaceutical company’s stock after selling 1,162 shares during the period. Pfizer accounts for about 1.1% of Aviva PLC’s portfolio, making the stock its 12th largest holding. Aviva PLC owned 0.34% of Pfizer worth $188,705,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of PFE. Fisher Asset Management LLC grew its position in Pfizer by 3.9% in the second quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock worth $1,143,248,000 after acquiring an additional 1,275,832 shares during the period. Schwab Charles Investment Management Inc. grew its position in Pfizer by 6.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 33,274,658 shares of the biopharmaceutical company’s stock worth $1,117,696,000 after acquiring an additional 2,013,835 shares during the period. Legal & General Group Plc grew its position in Pfizer by 0.9% in the second quarter. Legal & General Group Plc now owns 31,463,283 shares of the biopharmaceutical company’s stock worth $1,056,857,000 after acquiring an additional 292,839 shares during the period. Macquarie Group Ltd. grew its position in Pfizer by 0.9% in the first quarter. Macquarie Group Ltd. now owns 24,683,746 shares of the biopharmaceutical company’s stock worth $844,431,000 after acquiring an additional 228,405 shares during the period. Finally, Bank of Montreal Can grew its position in Pfizer by 1.2% in the second quarter. Bank of Montreal Can now owns 18,534,159 shares of the biopharmaceutical company’s stock worth $622,562,000 after acquiring an additional 227,682 shares during the period. Institutional investors own 69.90% of the company’s stock.
Several brokerages recently weighed in on PFE. ValuEngine upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. J P Morgan Chase & Co set a $39.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, November 1st. Jefferies Group set a $39.00 price target on Pfizer and gave the stock a “neutral” rating in a research note on Thursday, November 16th. Berenberg Bank set a $36.00 price target on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, October 31st. Finally, Morgan Stanley upgraded Pfizer from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $35.00 to $39.00 in a research note on Wednesday, September 20th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $38.66.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period last year, the firm earned $0.61 earnings per share. analysts anticipate that Pfizer Inc. will post 2.59 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Friday, November 10th were paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.52%. The ex-dividend date was Thursday, November 9th. Pfizer’s payout ratio is currently 79.01%.
In related news, EVP Alexander R. Mackenzie sold 7,350 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $35.65, for a total value of $262,027.50. Following the transaction, the executive vice president now owns 117,432 shares of the company’s stock, valued at $4,186,450.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Alexander R. Mackenzie sold 14,700 shares of the stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the transaction, the insider now directly owns 117,432 shares in the company, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 60,280 shares of company stock worth $2,118,988. Insiders own 0.06% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2017/12/02/aviva-plc-cuts-holdings-in-pfizer-inc-pfe.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.